Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines

Author(s)

de Aquino, Iara Goncalves ^[1] ; Bastos, Debora Campanella ^{[1, 2]} ; Maria Cuadra-Zelaya, Florence Juana ^[1] ; Teixeira, Isadora Ferrari ^[1] ; Salo, Tuula ^{[3, 4, 5, 6]} ; Della Coletta, Ricardo ^[1] ; Graner, Edgard ^[1]

Affiliation

^[1] State Univ Campinas UNICAMP, Sch Dent Piracicaba, Dept Oral Diag, Av Limeira 901, BR-13414018 Piracicaba, SP - Brazil

^[2] State Univ Campinas UNICAMP, Sch Dent Piracicaba, Dept Morphol, Piracicaba, SP - Brazil

^[3] Univ Helsinki, Inst Oral & Maxillofacial Dis, Helsinki - Finland

^[4] Helsinki Univ Hosp, HUSLAB, Dept Pathol, Helsinki - Finland

^[5] Univ Oulu, Oulu Univ Hosp, Fac Med, Canc & Translat Med Res Unit, Oulu - Finland

^[6] Univ Oulu, Med Res Ctr Oulu, Oulu Univ Hosp, Oulu - Finland

• Document type: Journal article
• Source: ARCHIVES OF ORAL BIOLOGY; v. 113, MAY 2020.
• Web of Science Citations: 0

Abstract

Objective: Fatty acid synthase (FASN) is overexpressed in several human cancers, including oral squamous cell carcinoma (OSCC). TVB-3166 is a recently described FASN inhibitor with antitumor effects and potential clinical relevance. The objective of this study was to evaluate the effects of TVB-3166 on OSCC cell lines. Materials and methods: The OSCC cell line SCC-9 modified to express ZsGreen (ZsG) (SCC-9 ZsG) and its in vivo selected metastatic derivative LN-1A were used to evaluate anticancer properties of TVB-3166. Cell viability was determined using MTT assays and proliferation determined by cell counting in a Neubauer chamber. Cell death and cell cycle progression were analyzed by Annexin V-PE/7-ADD-PerCP labeling and PI staining, respectively. Cell migration was assayed by scratch assays and cell adhesion using myogel. Production of FASN, p-AKT, CPT1-alpha, and epithelial-mesenchymal transition (EMT) markers were examined by Western blotting. Results: TVB-3166 significantly reduced cell viability and proliferation, promoted cell cycle arrest and apoptosis, and increased adhesion to myogel in both OSCC cell lines. Finally, the drug reduced SCC-9 ZsG migration. Conclusion: Our results demonstrated that TVB-3166 has anticancer effects on both SCC-9 ZsG and its metastatic version LN-1A, which are worthy of investigation in preclinical models for OSCC. (AU)

• FAPESP's process: 14/20832-3 - The association of Orlistat with chemotherapic agents for the treatment of oral squamous cell carcinoma: an in vitro and in vivo study in orthotopic models
• Grantee: Edgard Graner
• Support Opportunities: Regular Research Grants